University College London researchers have extended fruit fly lifespans by 48% using a combination of three drugs already approved for human use. This breakthrough, published in Proceedings of the National Academy of Sciences (PNAS), paves the way for novel treatments against age-related diseases.
Life expectancy in France has soared from 25 years in 1740 to over 80 years today (79.5 years for men and 85.4 for women), thanks to improved nutrition, healthcare, and sanitation. However, longer lives often bring more age-related conditions like arthritis, cardiovascular disease, cancer, and Alzheimer's. The goal: extend healthy years without the burden of these diseases.
To unravel aging's complexities, scientists study short-lived model organisms like Drosophila fruit flies, which typically live about 30 days. In this PNAS study, UCL experts combined three human-approved drugs targeting distinct cellular pathways.
The drugs—lithium (a mood stabilizer), trametinib (a cancer therapy), and rapamycin (an immune regulator)—each extend fruit fly life by about 11% alone. Together, they boosted lifespan by 48%, surpassing additive effects through complementary actions that neutralize side effects. For instance, rapamycin's impact on fat metabolism vanishes when paired with lithium.
This is an early milestone. Next steps include mouse trials, potentially leading to human studies. As the researchers emphasize, the aim isn't to "cheat death" but to "improve healthspan in older adults."
This isn't the first such success: last year, scientists nearly doubled the lifespan of Caenorhabditis elegans worms using three drugs, including rapamycin.
Source
Related articles:
